784 related articles for article (PubMed ID: 18838714)
41. Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study.
Tebbi CK; Mendenhall N; London WB; Williams JL; de Alarcon PA; Chauvenet AR;
Pediatr Blood Cancer; 2006 Feb; 46(2):198-202. PubMed ID: 16136581
[TBL] [Abstract][Full Text] [Related]
42. [Over 30-year experience of Polish Pediatric Leukemia/Lymphoma Study Group for treatment of Hodgkin's disease in children and adolescents: improvement curability and decrease of serious complications].
Balwierz W; Moryl-Bujakowska A; Depowska T; Klekawka T; Stanuch H; Matysiak M; Sopyło B; Kołakowska-Mrozowska B; Krenke K; Chybicka A; Raś M; Sońta-Jakimczyk D; Moszant A; Wachowiak J; Kaczmarek-Kanold M; Kowalczyk J; Odój T; Balcerska A; Drozyńska E; Wysocki M; Kołtan A; Krawczuk-Rybak M; Stolarska M
Przegl Lek; 2004; 61 Suppl 2():33-9. PubMed ID: 15688474
[TBL] [Abstract][Full Text] [Related]
43. Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884).
Aleman BM; Girinsky T; van der Maazen RW; Strijk S; Meijnders P; Bortolus R; Olofsen-van Acht MJ; Lybeert ML; Lievens Y; Eghbali H; Noordijk EM; Tomsic R; Meerwaldt JH; Poortmans PM; Smit WG; Pinna A; Henry-Amar M; Raemaekers JM; ;
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1184-90. PubMed ID: 15936157
[TBL] [Abstract][Full Text] [Related]
44. Involved-field radiation therapy for inoperable non small-cell lung cancer.
Rosenzweig KE; Sura S; Jackson A; Yorke E
J Clin Oncol; 2007 Dec; 25(35):5557-61. PubMed ID: 17984185
[TBL] [Abstract][Full Text] [Related]
45. Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?
Kahn S; Flowers C; Xu Z; Esiashvili N
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):175-80. PubMed ID: 20732769
[TBL] [Abstract][Full Text] [Related]
46. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma.
Moser EC; Kluin-Nelemans HC; Carde P; Meerwaldt JH; Tirelli U; Aleman BM; Baars J; Thomas J; van Glabbeke M; Noordijk EM
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1168-77. PubMed ID: 16887289
[TBL] [Abstract][Full Text] [Related]
47. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
[TBL] [Abstract][Full Text] [Related]
48. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group.
Schellong G; Dörffel W; Claviez A; Körholz D; Mann G; Scheel-Walter HG; Bökkerink JP; Riepenhausen M; Lüders H; Pötter R; Rühl U;
J Clin Oncol; 2005 Sep; 23(25):6181-9. PubMed ID: 16135485
[TBL] [Abstract][Full Text] [Related]
49. MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma.
De Sanctis V; Finolezzi E; Osti MF; Grapulin L; Alfò M; Pescarmona E; Berardi F; Natalino F; Moleti ML; Di Rocco A; Enrici RM; Foà R; Martelli M
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1154-60. PubMed ID: 18472357
[TBL] [Abstract][Full Text] [Related]
50. [Questions and aspects of radiotherapy of adult patients with localized supradiaphragmatic stage (CS I/II) Hodgkin's disease. 1. Questions and aspects on indications for primary and adjuvant radiotherapy].
Glanzmann C; Lütolf UM
Strahlenther Onkol; 1993 Aug; 169(8):449-58. PubMed ID: 8356505
[TBL] [Abstract][Full Text] [Related]
51. [Results of the radiotherapy of Hodgkin's disease (a JLRTG report). Japan Lymphoma Radiation Therapy Group].
Ikeda H; Masaki N; Hayabuchi N; Niibe H; Morita K; Watanabe S; Kaneta K; Horiuchi J
Gan No Rinsho; 1988 Apr; 34(5):685-92. PubMed ID: 3385934
[TBL] [Abstract][Full Text] [Related]
52. Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin's lymphoma.
Aref A; Narayan S; Tekyi-Mensah S; Varterasian M; Dan M; Eilender D; Karanes C; al-Katib A
Radiat Oncol Investig; 1999; 7(3):186-91. PubMed ID: 10406061
[TBL] [Abstract][Full Text] [Related]
53. [Follicle centre lymphoma: treatment results for stage I and II].
Neumann H; Blanck H; Koch R; Fiedler S; Lesche A; Herrmann T
Strahlenther Onkol; 2003 Dec; 179(12):840-6. PubMed ID: 14652673
[TBL] [Abstract][Full Text] [Related]
54. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.
Hoppe BS; Moskowitz CH; Filippa DA; Moskowitz CS; Kewalramani T; Zelenetz AD; Yahalom J
J Clin Oncol; 2008 Apr; 26(11):1858-64. PubMed ID: 18332466
[TBL] [Abstract][Full Text] [Related]
55. [Combination chemotherapy with total or subtotal lymphatic irradiation in the treatment of lymphogranulomatosis, stage IIIA or IIIB (based on five- and ten-year results)].
Kanaev SV; Gershanovich ML; Malinin AP
Vopr Onkol; 1997; 43(1):32-8. PubMed ID: 9133084
[TBL] [Abstract][Full Text] [Related]
56. Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group.
Eichenauer DA; Bredenfeld H; Haverkamp H; Müller H; Franklin J; Fuchs M; Borchmann P; Müller-Hermelink HK; Eich HT; Müller RP; Diehl V; Engert A
J Clin Oncol; 2009 Dec; 27(36):6079-85. PubMed ID: 19901121
[TBL] [Abstract][Full Text] [Related]
57. The impact of involved field radiation therapy in the treatment of relapsed or refractory non-Hodgkin lymphoma with high-dose chemotherapy followed by hematopoietic progenitor cell transplant.
Wendland MM; Smith DC; Boucher KM; Asch JD; Pulsipher MA; Thomson JW; Shrieve DC; Gaffney DK
Am J Clin Oncol; 2007 Apr; 30(2):156-62. PubMed ID: 17414465
[TBL] [Abstract][Full Text] [Related]
58. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.
Martin WG; Ristow KM; Habermann TM; Colgan JP; Witzig TE; Ansell SM
J Clin Oncol; 2005 Oct; 23(30):7614-20. PubMed ID: 16186594
[TBL] [Abstract][Full Text] [Related]
59. Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience.
Mazzarotto R; Boso C; Vianello F; Aversa MS; Chiarion-Sileni V; Trentin L; Zambello R; Muzzio PC; Fiore D; Sotti G
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):823-9. PubMed ID: 17379431
[TBL] [Abstract][Full Text] [Related]
60. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma.
Paumier A; Ghalibafian M; Beaudre A; Ferreira I; Pichenot C; Messai T; Lessard NA; Lefkopoulos D; Girinsky T
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):199-205. PubMed ID: 21481723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
